AIMS/HYPOTHESIS: IGFs and their binding proteins are increasingly recognised as important in understanding the pathogenesis of cardiovascular disease. Low IGFBP-1, particularly coupled with low IGF-I, is associated with increased cardiovascular risk. In relation to structural and regulatory parallels between IGFBP-1 and - 2 we have now examined the hypothesis that IGFBP-2 may be a marker for cardiovascular risk. METHODS: Fasting IGFBP-2, IGFBP-1, IGFBP-3, IGF-I, IGF-II, insulin, C-peptide, glucose, lipids, NEFAs, and HbA1c were measured in a cohort of 163 patients with type 2 diabetes. Individuals were categorised according to the presence or absence of the metabolic syndrome. RESULTS: Patients with the metabolic syndrome had a lower IGFBP-2 concentration. Low circulating IGFBP-2 was associated with elevated fasting glucose (rho = - 0.23, p = 0.003). IGFBP-2 correlated negatively with triglycerides (rho = - 0.19, p = 0.01) and LDL-cholesterol (rho = - 0.20, p = 0.01), and positively with insulin sensitivity (HOMA-S) (rho = 0.26, p = 0.02). Multivariate logistic regression demonstrated that low IGFBP-2 was independently associated with an increased risk of the metabolic syndrome (OR 0.31 [95 % CI 0.11 - 0.90]; p = 0.03). IGFBP-3 did not differ according to the presence or absence of metabolic syndrome. CONCLUSION/ INTERPRETATION: Low IGFBP-2 is associated with multiple cardiovascular risk factors similarly to IGFBP-1. Such associations were not apparent for IGFBP-3. Lack of marked prandial regulation of IGFBP-2, in contradistinction to IGFBP-1, may make IGFBP-2 a more robust biomarker for identification of insulin-resistant individuals at high cardiovascular risk in epidemiological studies.
AIMS/HYPOTHESIS: IGFs and their binding proteins are increasingly recognised as important in understanding the pathogenesis of cardiovascular disease. Low IGFBP-1, particularly coupled with low IGF-I, is associated with increased cardiovascular risk. In relation to structural and regulatory parallels between IGFBP-1 and - 2 we have now examined the hypothesis that IGFBP-2 may be a marker for cardiovascular risk. METHODS: Fasting IGFBP-2, IGFBP-1, IGFBP-3, IGF-I, IGF-II, insulin, C-peptide, glucose, lipids, NEFAs, and HbA1c were measured in a cohort of 163 patients with type 2 diabetes. Individuals were categorised according to the presence or absence of the metabolic syndrome. RESULTS:Patients with the metabolic syndrome had a lower IGFBP-2 concentration. Low circulating IGFBP-2 was associated with elevated fasting glucose (rho = - 0.23, p = 0.003). IGFBP-2 correlated negatively with triglycerides (rho = - 0.19, p = 0.01) and LDL-cholesterol (rho = - 0.20, p = 0.01), and positively with insulin sensitivity (HOMA-S) (rho = 0.26, p = 0.02). Multivariate logistic regression demonstrated that low IGFBP-2 was independently associated with an increased risk of the metabolic syndrome (OR 0.31 [95 % CI 0.11 - 0.90]; p = 0.03). IGFBP-3 did not differ according to the presence or absence of metabolic syndrome. CONCLUSION/ INTERPRETATION: Low IGFBP-2 is associated with multiple cardiovascular risk factors similarly to IGFBP-1. Such associations were not apparent for IGFBP-3. Lack of marked prandial regulation of IGFBP-2, in contradistinction to IGFBP-1, may make IGFBP-2 a more robust biomarker for identification of insulin-resistant individuals at high cardiovascular risk in epidemiological studies.
Authors: Michel Bernier; Dylan Harney; Yen Chin Koay; Antonio Diaz; Abhishek Singh; Devin Wahl; Tamara Pulpitel; Ahmed Ali; Vince Guiterrez; Sarah J Mitchell; Eun-Young Kim; John Mach; Nathan L Price; Miguel A Aon; David G LeCouteur; Victoria C Cogger; Carlos Fernandez-Hernando; John O'Sullivan; Mark Larance; Ana Maria Cuervo; Rafael de Cabo Journal: NPJ Aging Mech Dis Date: 2020-07-21
Authors: Annewieke W van den Beld; Olga D Carlson; Maire E Doyle; Dimitris Rizopoulos; Luigi Ferrucci; Aart Jan van der Lely; Josephine M Egan Journal: Eur J Endocrinol Date: 2019-02-01 Impact factor: 6.664
Authors: Ravi V Shah; Shih-Jen Hwang; Ashish Yeri; Kahraman Tanriverdi; Alexander R Pico; Chen Yao; Venkatesh Murthy; Jennifer Ho; Olga Vitseva; Danielle Demarco; Sajani Shah; Mark D Iafrati; Daniel Levy; Jane E Freedman Journal: Arterioscler Thromb Vasc Biol Date: 2019-01 Impact factor: 8.311
Authors: Sulin Wu; Rebecca Mar-Heyming; Eric Z Dugum; Nicholas A Kolaitis; Hongxiu Qi; Päivi Pajukanta; Lawrence W Castellani; Aldons J Lusis; Thomas A Drake Journal: Hum Mol Genet Date: 2009-12-08 Impact factor: 6.150
Authors: Marc Birringer; Doreen Kuhlow; Paul T Pfluger; Nico Landes; Tim J Schulz; Markus Glaubitz; Simone Florian; Andreas Pfeiffer; Markus Schuelke; Regina Brigelius-Flohé; Michael Ristow Journal: Eur J Nutr Date: 2007-09-19 Impact factor: 5.614